Literature DB >> 18089865

Randomized crossover study evaluating the effect of gemcitabine infusion dose rate: evidence of auto-induction of gemcitabine accumulation.

Peter Grimison1, Peter Galettis, Susan Manners, Maria Jelinek, Ekkaphon Metharom, Paul L de Souza, Winston Liauw, Matthew J Links.   

Abstract

PURPOSE: Controversy exists over the optimal dose rate for administration of gemcitabine. There is a strong pharmacologic rationale for increased intracellular accumulation with prolonged infusions, but this failed to translate into a significant benefit in a large randomized study. The purpose of this study was to compare the intracellular pharmacokinetics of gemcitabine given for 30 minutes or for 100 minutes in a crossover design. PATIENTS AND METHODS: We randomly assigned 33 patients to a standard dose of 1,000 mg/m2 over either 30 minutes or 100 minutes. At the second week, they were transferred to the alternate schedule. Blood samples were collected at various times after the gemcitabine infusion. Gemcitabine and difluorodeoxyuridine were measured in plasma by high-performance liquid chromatography (HPLC), and gemcitabine-triphosphate was measured by HPLC in leukocytes.
RESULTS: Intracellular accumulation was greater during the 100-minute infusion, which was consistent with previous data. This effect was confounded by an increase in gemcitabine-triphosphate accumulation between weeks 1 and 2, which was consistent with self-induction of gemcitabine accumulation. There was significant heterogeneity: 27% of patients had greater WBC accumulation during the 30-minute infusion (regardless of treatment order). Patients with relatively greater levels of gemcitabine-triphosphate in WBCs tended to have less under-dosing and a greater reduction in midcycle neutrophils. However, this observation did not correlate with plasma gemcitabine levels.
CONCLUSION: This work identifies significant variations in intracellular gemcitabine-triphosphate accumulation between and within individuals, and it provides evidence that this variation has potential clinical significance. The observed self-induction of gemcitabine metabolism has broad implications for the dosing of nucleoside analogs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18089865     DOI: 10.1200/JCO.2007.10.7078

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  6 in total

1.  Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours.

Authors:  Milena Gusella; Felice Pasini; Caterina Bolzonella; Silvia Meneghetti; Carmen Barile; Antonio Bononi; Silvia Toso; Daniela Menon; Giorgio Crepaldi; Yasmina Modena; Laura Stievano; Roberto Padrini
Journal:  Br J Clin Pharmacol       Date:  2011-03       Impact factor: 4.335

Review 2.  Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a review.

Authors:  Meredith A Morgan; Leslie A Parsels; Jonathan Maybaum; Theodore S Lawrence
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

3.  Pharmacokinetics of gemcitabine at fixed-dose rate infusion in patients with normal and impaired hepatic function.

Authors:  Alessandra Felici; Susanna Di Segni; Michele Milella; Simona Colantonio; Isabella Sperduti; Barbara Nuvoli; Michela Contestabile; Andrea Sacconi; Massimo Zaratti; Gennaro Citro; Francesco Cognetti
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

4.  Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2',2'-difluorodeoxyuridine and their nucleotides.

Authors:  Ellen J B Derissen; Alwin D R Huitema; Hilde Rosing; Jan H M Schellens; Jos H Beijnen
Journal:  Br J Clin Pharmacol       Date:  2018-04-16       Impact factor: 4.335

Review 5.  Intracellular Pharmacokinetics of Pyrimidine Analogues used in Oncology and the Correlation with Drug Action.

Authors:  Ellen J B Derissen; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2020-12       Impact factor: 6.447

6.  SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours.

Authors:  A Khatri; B W Williams; J Fisher; R C Brundage; V J Gurvich; L G Lis; K M Skubitz; A Z Dudek; E W Greeno; R A Kratzke; J K Lamba; M N Kirstein
Journal:  Br J Cancer       Date:  2013-12-03       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.